Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems

被引:54
作者
Benjamin, Richard J. [1 ]
Braschler, Thomas [2 ]
Weingand, Tina [3 ]
Corash, Laurence M. [1 ]
机构
[1] Cerus Corp, 2550 Stanwell Dr, Concord, CA 94520 USA
[2] Luzerner Kantonsspital, Luzern, Switzerland
[3] Blutspendedienst Zentralschweiz SRK, Luzern, Switzerland
关键词
INDUCED IMMUNE THROMBOCYTOPENIA; DRUG-INDUCED IMMUNE; AUTOIMMUNE HEMOLYTIC-ANEMIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; EVANS-SYNDROME; RENAL-FAILURE; TRANSPLANTATION; TACROLIMUS; MANAGEMENT; LIVER;
D O I
10.1111/trf.14284
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Delayed, large-volume bacterial culture and amotosalen/ultraviolet-A light pathogen reduction are effective at reducing the risk of bacterial proliferation in platelet concentrates (PCs). Hemovigilance programs continue to receive reports of suspected septic transfusion reactions, most with low imputability. Here, we compile national hemovigilance data to determine the relative efficacy of these interventions. STUDY DESIGN AND METHODS: Annual reports from the United Kingdom, France, Switzerland, and Belgium were reviewed between 2005 and 2016 to assess the risk of bacterial contamination and septic reactions. RESULTS: Approximately 1.65 million delayed, large-volume bacterial culture-screened PCs in the United Kingdom and 2.3 million amotosalen/ultraviolet-A-treated PCs worldwide were issued with no reported septic fatalities. One definite, one possible, and 12 undetermined/indeterminate septic reactions and eight contaminated "near misses" were reported with delayed, large-volume bacterial cultures between 2011 and 2016, for a lower false-negative culture rate than that in the previous 5 years (5.4 vs. 16.3 per million: odds ratio, 3.0; 95% confidence interval, 1.4-6.5). Together, the Belgian, Swiss, and French hemovigilance programs documented zero probable or definite/certain septic reactions with 609,290 amotosalen/ultraviolet-A-treated PCs (<1.6 per million). The rates were significantly lower than those reported with concurrently transfused, nonpathogen-reduced PCs in Belgium (<4.4 vs. 35.6 per million: odds ratio, 8.1; 95% confidence interval, 1.1-353.3) and with historic septic reaction rates in Switzerland (<6.0 vs. 82.9 per million: odds ratio, 13.9; 95% confidence interval, 2.1-589.2), and the rates tended to be lower than those from concurrently transfused, nonpathogen-reduced PCs in France (<4.7 vs. 19.0 per million: odds ratio, 4.1; 95% confidence interval, 0.7-164.3). CONCLUSION: Pathogen reduction and bacterial culture both reduced the incidence of septic reactions, although under-reporting and strict imputability criteria resulted in an underestimation of risk.
引用
收藏
页码:2946 / 2957
页数:12
相关论文
共 25 条
[1]  
ABUELMAGD KM, 1991, TRANSPLANT P, V23, P3190
[2]   Haemolytic anaemia and renal failure associated with antibodies to trimethoprim and sulfamethoxazole [J].
Arndt, P. A. ;
Garratty, G. ;
Wolf, C. F. W. ;
Rivera, M. .
TRANSFUSION MEDICINE, 2011, 21 (03) :194-198
[3]  
Arndt Patricia A, 2014, Immunohematology, V30, P44
[4]   Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management [J].
Aster, R. H. ;
Curtis, B. R. ;
McFarland, J. G. ;
Bougie, D. W. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (06) :911-918
[5]   Current concepts - Drug-induced immune thrombocytopenia [J].
Aster, Richard H. ;
Bougie, Daniel W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (06) :580-587
[6]  
Bonham C A, 1996, Transpl Immunol, V4, P186, DOI 10.1016/S0966-3274(96)80015-3
[7]   Drug-induced haemolysis, renal failure, thrombocytopenia and lactic acidosis in patients with HIV and cryptococcal meningitis: a diagnostic challenge [J].
Camara-Lemarroy, Carlos R. ;
Flores-Cantu, Hazael ;
Calderon-Hernandez, Hector J. ;
Diaz-Torres, Marco A. ;
Villareal-Velazquez, Hector J. .
INTERNATIONAL JOURNAL OF STD & AIDS, 2015, 26 (14) :1052-1054
[8]   Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole [J].
Chisholm-Burns, Marie A. ;
Patanwala, Asad E. ;
Spivey, Christina A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (02) :123-127
[9]  
DiGiuseppe JA, 1996, ARCH PATHOL LAB MED, V120, P282
[10]   Successful treatment of Evans syndrome post liver transplant with splenectomy and switch from tacrolimus to cyclosporine [J].
Domenech, C. ;
Mialou, V. ;
Galambrun, C. ;
Lachaux, A. ;
Mure, P. Y. ;
Dijoud, F. ;
Bertrand, Y. .
TRANSPLANT INTERNATIONAL, 2008, 21 (04) :397-399